← Back to Search

Behavioral Intervention

Educational Nudge Intervention for Overmedication in People Living With Dementia

N/A

Waitlist Available

Led By Donovan Maust, MD, MS

Research Sponsored by University of Michigan

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, 4 months (after sending the educational tool)

Awards & highlights

Study Summary

This trial will help reduce medications for people with dementia to improve their care.

Who is the study for?

This trial is for people with dementia or mild cognitive impairment who are being treated at selected Michigan Medicine and Henry Ford Health System clinics. Participants must be taking three or more medications that affect the central nervous system, like antidepressants or opioids.Check my eligibility

What is being tested?

The study tests an educational 'nudge' designed to reduce the use of multiple mind-affecting drugs in those living with dementia. It aims to lower the total daily dosage of these medications over a four-month period.See study design

What are the potential side effects?

Since this intervention is educational, it does not involve direct medical treatments or drugs; therefore, traditional physical side effects are not expected. However, changes in medication regimens could lead to withdrawal symptoms or changes in behavior.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, 4 months (after sending the educational tool)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, 4 months (after sending the educational tool)

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 4 months (after sending the educational tool) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in the total standardized daily dosage (TSDD) of the medication classes contributing to CNS polyRx as measured in the EHR

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Educational nudge interventionExperimental Treatment1 Intervention

Participants will be mailed the educational tool in the form of a brochure.

Group II: No educational toolActive Control1 Intervention

This arm will collect data on total standardized daily dosage of the medication classes contributing to CNS polyRx from the Electronic Medical Record (EMR).

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Educational nudge intervention

2023

N/A

~150

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of MichiganLead Sponsor

1,795 Previous Clinical Trials

6,373,790 Total Patients Enrolled

9 Trials studying Dementia

1,570 Patients Enrolled for Dementia

National Institute on Aging (NIA)NIH

1,669 Previous Clinical Trials

28,004,968 Total Patients Enrolled

265 Trials studying Dementia

23,623,265 Patients Enrolled for Dementia

Donovan Maust, MD, MSPrincipal InvestigatorUniversity of Michigan

Media Library

N/A (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05628181 — N/A

Dementia Research Study Groups: No educational tool, Educational nudge intervention

Dementia Clinical Trial 2023: N/A Highlights & Side Effects. Trial Name: NCT05628181 — N/A

N/A (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05628181 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still vacancies in this clinical experiment?

"The records available on clinicaltrials.gov indicate that this trial, which was published in February 28th of 2023 and updated last December 6th 2022, is not currently seeking participants; however, there are 424 alternative studies actively recruiting patients now."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Patient-facing Tool to Reduce Opioid-Psychotropic Polypharmacy in People Living With Dementia (PLWD)

Donovan Maust 2023. "A Patient-facing Tool to Reduce Opioid-Psychotropic Polypharmacy in People Living With Dementia (PLWD)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05628181.